Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047788 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00047788 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 30 participants.
The verdict
NCT00047788, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
Interventions
- DRUG ZD6474
- DRUG VEGF-receptor tyrosine kinase (KDR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-10 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047788
The ClinicalTrials.gov registry entry for NCT00047788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ZD6474 is the first listed.
NCT00047788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047788 about?
NCT00047788 is a clinical study titled "Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer". The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
What is the current status of trial NCT00047788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-10. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00047788?
The interventions under investigation include: ZD6474 (DRUG), VEGF-receptor tyrosine kinase (KDR) (DRUG).
Who is sponsoring clinical trial NCT00047788?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.